Publications
Detailed Information
Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Yeon Bi | - |
dc.contributor.author | Yang, Jeong Mi | - |
dc.contributor.author | Kwon, Hyun Jung | - |
dc.contributor.author | Lee, Jeong-Ok | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Paik, Jin Ho | - |
dc.date.accessioned | 2023-05-08T00:32:43Z | - |
dc.date.available | 2023-05-08T00:32:43Z | - |
dc.date.created | 2021-12-06 | - |
dc.date.created | 2021-12-06 | - |
dc.date.issued | 2021-11 | - |
dc.identifier.citation | Anticancer Research, Vol.41 No.11, pp.5677-5692 | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.uri | https://hdl.handle.net/10371/191864 | - |
dc.description.abstract | Background/Aim: Bruton's tyrosine kinase (BTK)-mediated B-cell-receptor signaling drives lymphomagenesis of diffuse large B-cell lymphoma (DLBCL). We investigated the clinicopathological significance of BTK positivity in DLBCL according to known molecules related to resistance to BTK inhibitors [BCL2 apoptosis regulator (BCL2)/MYC proto-oncogene, bHLH transcription factor (MYC)]. Patients and Methods: We evaluated BTK expression immunohistochemically in 106 DLBCLs considering their BCL2/MYC status. Results: Considering the whole cohort, BTK was expressed in 65.1%, including 70.4% (50/71) of non-germinal center B-cell-like (non-GCB) subtype; BCL2 expression was detected in 60.4%, MYC expression in 15.1%, MYC translocation in 4.2% (4/96) and MYC gain/amplification in 7.6% (8/105). Overall and in the non-GCB cohort, BTK positively correlated with high international prognostic index (both p=0.005) and stage (p=0.006 and p=0.002), and with BCL2 intensity (p=0.005 and p=0.026, respectively); MYC gain/amplification total cohort (p=0.038). Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Conclusion: BTK expression may be utilized to stratify risk in patients with DLBCL. | - |
dc.language | 영어 | - |
dc.publisher | International Institute of Anticancer Research | - |
dc.title | Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma | - |
dc.type | Article | - |
dc.identifier.doi | 10.21873/anticanres.15384 | - |
dc.citation.journaltitle | Anticancer Research | - |
dc.identifier.wosid | 000720235500017 | - |
dc.identifier.scopusid | 2-s2.0-85118863942 | - |
dc.citation.endpage | 5692 | - |
dc.citation.number | 11 | - |
dc.citation.startpage | 5677 | - |
dc.citation.volume | 41 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Lee, Jong Seok | - |
dc.contributor.affiliatedAuthor | Paik, Jin Ho | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | IBRUTINIB RESISTANCE | - |
dc.subject.keywordPlus | TEC FAMILY | - |
dc.subject.keywordPlus | DOUBLE-HIT | - |
dc.subject.keywordPlus | BTK | - |
dc.subject.keywordPlus | MYC | - |
dc.subject.keywordPlus | CONTRIBUTES | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TISSUE | - |
dc.subject.keywordAuthor | Bruton&apos | - |
dc.subject.keywordAuthor | s tyrosine kinase | - |
dc.subject.keywordAuthor | BCL2 | - |
dc.subject.keywordAuthor | c-MYC | - |
dc.subject.keywordAuthor | diffuse large B-cell Lymphoma | - |
dc.subject.keywordAuthor | prognosis | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.